Alignment Health Plan has partnered with Astrana Health to expand access to primary and specialty care for Medicare Advantage members across seven counties in California, including Los Angeles and San Francisco. Starting January 1, 2027, members will benefit from a network of 3,000 primary care providers and 6,500 specialists offering multilingual and culturally responsive care. This collaboration aims to serve California's diverse senior population by providing trusted local doctors and personalized support to improve health outcomes. Medicare enrollment for these plans runs until December 7, 2026, with coverage starting in 2027.
Alignment Health Plan and Astrana Health partnership offers context for healthcare sector investors. For readers following health stocks, here is Pluang's market snapshot as of Oct 19, 2026 21:21 WIB: out of 150 priced US health stocks, 90 rose and 55 fell. Notable movers include IBRX at USD 8.57 (-6.64%), DYN at USD 15.08 (+5.82%), and SLS at USD 10.48 (+5.06%). Typical hold times range from 3 to 4 days.
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
AIOS Tech Inc. announced an agreement to acquire SmartCore Holdings Limited in an all-stock transaction valued at approximately $100 million. The deal will issue 33.3 million AIOS shares to SmartCore's sellers, who will hold about 80% of AIOS shares ...
Bill Gross, a serial entrepreneur behind over 175 companies, has launched Idealab.ai, a platform using AI to generate and share over 1.2 million business ideas based on real-world problems. The platform aims to lower barriers to entrepreneurship by h...
The Portnoy Law Firm has launched an investigation into Cardinal Infrastructure Group for possible securities fraud following the company's Q2 2026 financial report. Cardinal revealed a decline in its gross profit margin to 10.8%, down from 13.9% the...
XBiotech announced positive results from the Phase II TASKIN trial, where their antibody vilamakitug combined with standard chemotherapy improved 12-month overall survival to 61.3% in refractory metastatic colorectal cancer patients, surpassing the s...
